Krylov Y.V.*, Lesnichaya O.V.**, Krylov A.Y.***, Krylov E.Y.**
Immunohistochemical diagnosing of the hormone-receptor status of breast carcinoma with a prognosis of the main trends in antitumoral drug therapy
*Institute of Public Health " Vitebsk Regional Clinic Pathoanatomical bureau", Republic of Belarus
**Education Establishment "Vitebsk State Order of Peoples’ Friendship Medical University", Republic of Belarus
***State Education Establishment "Institute of refresher training and further training of staff of State committee of forensic medical examinations of the Republic of Belarus", Republic of Belarus
Abstract.
The data on the cost of immunohistochemical diagnosing of the hormone-receptor status and the diagnostic coverage of the women operated for breast carcinoma (BC) in the regions of the Republic of Belarus are presented. During 2008–2013 the percentage of hormone-receptor examination coverage of the BC patients was as follows: Brest region – 85,1%, Vitebsk region – 61,9%, Mogilev region – 88,1%, Gomel region – 98,6%. The made pharmacoeconomic analysis of the hormone-receptor status of BC has shown that these examinations constitute a significant part of all IHC examinations in the regional pathoanatomical bureaus and are lower in cost than the analysis of HER2/neu. At the same time, the hormone-receptor status analysis helps to define a considerable group of patients with BC, who have a more favourable prognosis, which requires less expensive hormone therapy. According to the Cancer Registry of the Vitebsk region 500 cases of breast cancer were diagnosed in 2014. The hormone-receptor status and HER2/neu analyses were made in the oncomorphology department in 425 cases. Estrogen and progesterone receptors were immunohistochemically revealed in 54,1% of cases, and the reaction was negative in 34,1% of cases. At the same time 82 cases were characterized by triple negative cancer, which constituted 20% of the total number of invasive breast cancer. The obtained data with the percentage of HER2/neu hyperexpression taken into account help to determine the proportion of women requiring hormonal, targeted and cytostatic therapies.
Key words: breast carcinoma, immunohistochemical diagnosing of hormone-receptor status and HER2/neu, pharmacoeconomic analysis.
References
1. Paltsev MA, red. Zaletaev DV, red. Sistemy geneticheskikh i epigeneticheskikh markerov v diagnostike onkologicheskikh zabolevanii [Systems genetic and the epigeneticheskikh of markers in diagnosis of oncologic diseases]. Moscow, RF: Meditsina; 2009. 384 р.
2. Sukonko OG, red. Krasnyi SA, red. Algoritmy diagnostiki i lecheniia zlokachestvennykh novoobrazovanii [Algorithms of diagnostics and treatment of malignant neoplasms]: sb. nauch. st. Minsk, RB: Professional'nye izdaniia; 2012. Vyp. 2. 508 р.
3. Pozharisskiy KM, Leenman EE. Znachenie immunogistokhimicheskikh metodik dlia opredeleniia kharaktera lecheniia i prognoza opukholevykh zabolevanii [Value of immunohistochemical techniques for determination of nature of treatment and the forecast of tumoral diseases]. Arkhiv patologii. 2000;62(5):3–11.
4. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998 Feb;11(2):155–68.
5. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011 Jul;121(7):2750–67.
6. Geisler J. et al. Letrozole suppresses tissue and plasma estradiol, estrone and estrone sulfate more effectively compared to anastrozole. Breast Cancer Res Treat. 2006;100(1):23.
7. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary of early breast cancer 2007. Ann Oncol. 2007 Jul;18(7):1133–44.
8. Cortés J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, Baselga J. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012 May;30(14):1594–600.
9. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. Phase II Trial of Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. J Clin Oncol. 2010 Mar;28(7):1138–44.
10. Krylov YuV, Krylov EYu. Analiz zadach i podkhodov k ratsional'nomu ispol'zovaniiu sredstv dlia immunogistokhimicheskoi diagnostiki v Respublike Belarus' [The analysis of tasks and approaches to rational use of agents for immunohistochemical diagnostics in Republic of Belarus]. Vestnik Vitebskogo gosudarstvennogo meditsinskogo universiteta. 2013;12(2):55–62.
11. Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Оperative «Arimidex» Compared to Tamoxifen (PROACT) trial. Cancer. 2006 May;106(10):2095–103.
12. Sukhanov SA, Lozhkin EA, Shcherbina AS, Kiryanov NA. Patomorfologicheskaia kharakteristika raka molochnoi zhelezy v Udmurtii [The pathomorphologic characteristic of a breast cancer in Udmurtia]. Zdorov'e, demografiia, ekologiia finno-ugorskikh narodov. 2014;(30):85–8.
13. Zavialova MV. i dr. Vozmozhnosti prognozirovaniia gematogennogo metastazirovaniia pri raznykh gistogeneticheskikh tipakh raka molochnoi zhelezy [Possibilities of forecasting of a hematogenic innidiation at different the gistogeneticheskikh types of a breast cancer]. V: Kazachkov EL, red. Aktual'nye voprosy patologoanatomicheskoi praktiki. Chelyabinsk, RF; 2013. р. 32–34.
14. Cetin I, Topcul M. Triple Negative Breast Cancer. Asian Pac J Cancer Prev. 2014;15(6):2427–31.
15. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. Natl Cancer Inst. 2014 Apr;106(5).
16. Miron L, Marinca A, Marinca M, Miron I. Triple-negative breast cancer – towards a new entity. Rev Med Chir Soc Med Nat Iasi. 2008 Jan-Mar;112(1):51–8.
17. Vargas Wolfgramm E, Gavioli CF, Entringer ML, Alves LN, Stur E, DE Castro Neto AK, Motta LL, Pereira FE, Louro ID. Histological profile and age at diagnosis of breast cancer and ovarian tumors: A register-based study in Espirito Santo, Brazil. Mol Clin Oncol. 2013 Mar;1(2):353–358.
18. Mdpaiman N, Md Ali SA, Mdzin R, Meor Kamal MZ, Md Amin WA, Nallusamy M, Puspanathan P, Muhammad R, Wan Puteh SE, Das S. Estrogen receptor-negative breast ductal carcinoma: clinicopathological features and MIB-1 (Ki-67) proliferative index association. PLoS One. 2014 Feb;9(2):e89172.
19. Offersen BV, Sørensen FB, Knoop A, Overgaard J. The prognostic relevance of estimates of proliferative activity in early breast cancer. Histopathology. 2003 Dec;43(6):573–82.
